• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

N Engl J Med . Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months

tetano

Editor, Senior Moderator
N Engl J Med


. 2021 Oct 6.
doi: 10.1056/NEJMoa2114583. Online ahead of print.
Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months


Einav G Levin[SUP] 1 [/SUP], Yaniv Lustig[SUP] 1 [/SUP], Carmit Cohen[SUP] 1 [/SUP], Ronen Fluss[SUP] 1 [/SUP], Victoria Indenbaum[SUP] 1 [/SUP], Sharon Amit[SUP] 1 [/SUP], Ram Doolman[SUP] 1 [/SUP], Keren Asraf[SUP] 1 [/SUP], Ella Mendelson[SUP] 1 [/SUP], Arnona Ziv[SUP] 1 [/SUP], Carmit Rubin[SUP] 1 [/SUP], Laurence Freedman[SUP] 1 [/SUP], Yitshak Kreiss[SUP] 1 [/SUP], Gili Regev-Yochay[SUP] 1 [/SUP]



Affiliations

Abstract

Background: Despite high vaccine coverage and effectiveness, the incidence of symptomatic infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been increasing in Israel. Whether the increasing incidence of infection is due to waning immunity after the receipt of two doses of the BNT162b2 vaccine is unclear.
Methods: We conducted a 6-month longitudinal prospective study involving vaccinated health care workers who were tested monthly for the presence of anti-spike IgG and neutralizing antibodies. Linear mixed models were used to assess the dynamics of antibody levels and to determine predictors of antibody levels at 6 months.
Results: The study included 4868 participants, with 3808 being included in the linear mixed-model analyses. The level of IgG antibodies decreased at a consistent rate, whereas the neutralizing antibody level decreased rapidly for the first 3 months with a relatively slow decrease thereafter. Although IgG antibody levels were highly correlated with neutralizing antibody titers (Spearman's rank correlation between 0.68 and 0.75), the regression relationship between the IgG and neutralizing antibody levels depended on the time since receipt of the second vaccine dose. Six months after receipt of the second dose, neutralizing antibody titers were substantially lower among men than among women (ratio of means, 0.64; 95% confidence interval [CI], 0.55 to 0.75), lower among persons 65 years of age or older than among those 18 to less than 45 years of age (ratio of means, 0.58; 95% CI, 0.48 to 0.70), and lower among participants with immunosuppression than among those without immunosuppression (ratio of means, 0.30; 95% CI, 0.20 to 0.46).
Conclusions: Six months after receipt of the second dose of the BNT162b2 vaccine, humoral response was substantially decreased, especially among men, among persons 65 years of age or older, and among persons with immunosuppression.
 
Back
Top Bottom